Ionis Pharmaceuticals Inc
IONS42.660USD
+0.180+0.42%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
6.79BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Ionis Pharmaceuticals Inc Unternehmen
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Unternehmensinformationen
BörsenkürzelIONS
Name des UnternehmensIonis Pharmaceuticals Inc
IPO-datumMay 17, 1991
CEODr. Brett P. Monia, Ph.D.
Anzahl der mitarbeiter1069
WertpapierartOrdinary Share
GeschäftsjahresendeMay 17
Addresse2855 Gazelle Court
StadtCARLSBAD
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl92010
Telefon17609319200
Websitehttps://www.ionis.com/
BörsenkürzelIONS
IPO-datumMay 17, 1991
CEODr. Brett P. Monia, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.82K
-0.64%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
89.49K
-10.05%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.66K
+2.15%
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
48.55K
+0.86%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
47.47K
-16.75%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
+12.65%
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
15.94K
+101.50%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.82K
-0.64%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
89.49K
-10.05%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.66K
+2.15%
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Mar 4
Währung: USDAktualisiert: Tue, Mar 4
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.83%
The Vanguard Group, Inc.
10.47%
T. Rowe Price Investment Management, Inc.
10.07%
Capital World Investors
7.87%
BlackRock Institutional Trust Company, N.A.
5.47%
Andere
51.29%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.83%
The Vanguard Group, Inc.
10.47%
T. Rowe Price Investment Management, Inc.
10.07%
Capital World Investors
7.87%
BlackRock Institutional Trust Company, N.A.
5.47%
Andere
51.29%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
71.14%
Hedge Fund
16.49%
Investment Advisor/Hedge Fund
16.46%
Research Firm
2.04%
Private Equity
1.59%
Pension Fund
1.12%
Individual Investor
0.81%
Bank and Trust
0.66%
Sovereign Wealth Fund
0.28%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
2023Q2
770
142.08M
99.29%
+364.04K
2023Q1
825
136.59M
95.51%
-5.80M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
23.61M
14.84%
+924.09K
+4.07%
Mar 31, 2025
The Vanguard Group, Inc.
16.35M
10.27%
-88.61K
-0.54%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
16.18M
10.16%
+323.67K
+2.04%
Mar 31, 2025
Capital World Investors
12.36M
7.77%
+896.58K
+7.82%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.90M
5.59%
+21.73K
+0.24%
Mar 31, 2025
Bellevue Asset Management AG
7.85M
4.93%
-15.50K
-0.20%
Mar 31, 2025
Wellington Management Company, LLP
8.42M
5.29%
-255.73K
-2.95%
Mar 31, 2025
Deep Track Capital LP
4.56M
2.87%
+2.63M
+136.01%
Mar 31, 2025
State Street Global Advisors (US)
4.85M
3.04%
-581.28K
-10.71%
Mar 31, 2025
Two Sigma Investments, LP
3.78M
2.37%
+1.51M
+66.38%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Wed, Aug 6
Aktualisiert: Wed, Aug 6
Name
Anteil
Tema Neuroscience and Mental Health ETF
3.69%
ARK Genomic Revolution ETF
3.41%
Virtus LifeSci Biotech Products ETF
2.32%
SPDR S&P Biotech ETF
1.56%
WisdomTree BioRevolution Fund
1.35%
Tema Heart & Health ETF
1.08%
Direxion Daily S&P Biotech Bull 3X Shares
1.01%
Capital Group US Small and Mid Cap ETF
0.92%
iShares Health Innovation Active ETF
0.88%
Franklin Genomic Advancements ETF
0.83%
Mehr Anzeigen
Tema Neuroscience and Mental Health ETF
Anteil3.69%
ARK Genomic Revolution ETF
Anteil3.41%
Virtus LifeSci Biotech Products ETF
Anteil2.32%
SPDR S&P Biotech ETF
Anteil1.56%
WisdomTree BioRevolution Fund
Anteil1.35%
Tema Heart & Health ETF
Anteil1.08%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil1.01%
Capital Group US Small and Mid Cap ETF
Anteil0.92%
iShares Health Innovation Active ETF
Anteil0.88%
Franklin Genomic Advancements ETF
Anteil0.83%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
